Burosumab-Twza Injection (Crysvita)

Crysvita (burosumab‑twza) is covered for X‑linked hypophosphatemia (XLH) in patients aged ≥1 year and is excluded for children <1 year and patients with severe renal impairment/ESRD (CrCl <30 mL/min). Coverage requires genetic confirmation of a PHEX mutation, fasting serum phosphorus below the age‑specific reference range, discontinuation of oral phosphate and vitamin D analogues ≥1 week prior, adherence to weight‑based dosing (pediatric 0.8 mg/kg q2w; adult 1 mg/kg q4w, max 90 mg), specified phosphorus monitoring and withholding/re‑initiation rules, and approvals are issued for 6 months.

"Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older."

Sign up to see full coverage criteria, indications, and limitations.